Hormone-refractory prostate cancer
RecruitingA Study of Tulmimetostat and Luxdegalutamide Compared to Standard Treatment in Men with Advanced Prostate Cancer That No Longer Responds to Hormone Therapy
A Study of Tulmimetostat and Luxdegalutamide Compared to Standard Treatment in Men with Advanced Prostate Cancer That No Longer Responds to Hormone Therapy
- Disease:Hormone-refractory prostate cancer
- Substances:AbirateroneCabazitaxel+5
Denmark- Participants:18–64 years · 65+ years
- Substances:Abiraterone
- Sponsor:Novartis Pharma AG














